Cancer Research 09 AM Call for Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kisker, O.
Right arrow Articles by Pirie-Shepherd, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kisker, O.
Right arrow Articles by Pirie-Shepherd, S. R.
[Cancer Research 61, 7298-7304, October 1, 2001]
© 2001 American Association for Cancer Research

Tumor Biology

Generation of Multiple Angiogenesis Inhibitors by Human Pancreatic Cancer1

Oliver Kisker, Shinya Onizuka, Jacqueline Banyard, Tomoko Komiyama, Christian M. Becker, Eike Gert Achilles, Carmen M. Barnes, Michael S. O’Reilly, Judah Folkman2 and Steven R. Pirie-Shepherd

Laboratory of Surgical Research, Children’s Hospital, Boston, Massachusetts 02115 [O. K., S. O., J. B., C. M. Be., E. G. A., C. M. Ba., J. F., S. R. P-S.]; University Hospital Marburg, Department of General Surgery, Philipps University, Marburg, Germany [O. K.]; Department of Surgery II, Nagasaki University, Nagasaki Japan [S. O.]; Department of Biological Chemistry, University Michigan Medical School, Ann Arbor, Michigan 48109 [T. K.]; University Hospital Benjamin Franklin, Department of Gynecology and Obstetrics, Free University Berlin, Berlin, Germany [C. M. Be.]; University Hospital Hamburg, Department of Hepato-Biliary Surgery, University of Hamburg, Hamburg, Germany [E. G. A.]; Department of Radiation Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030 [M. S. O.]; Departments of Surgery and Cell Biology, Harvard Medical School, Boston, Massachusetts 02115 [J. F.]; and Attenuon LLC, San Diego, California 92121 [S. R. P-S.]

A primary inoculum of human pancreatic cancer cells (BxPC-3) has the ability to inhibit the growth of a secondary tumor in an in vivo animal model. Such ability suggests that the primary tumor is producing inhibitors that act at the site of the secondary tumor. Accordingly we attempted to discover which inhibitors are produced by pancreatic cancer cells. We determined that pancreatic cancer cells process angiostatin isoforms from plasminogen. Additionally, we isolated and characterized an uncleaved "latent" antiangiogenic antithrombin (aaAT) molecule processed from systemically available AT by pancreatic cancer cells as well as a cleaved form of aaAT processed from systemically available AT by pancreatic cancer cells. Human AT, cleaved with human neutrophil elastase, inhibits angiogenesis in the chorioallantoic membrane assay. This human aaAT molecule is able to inhibit the growth of pancreatic tumors in immune-compromised mice. Our work represents the first demonstration of multiple angiogenesis inhibitors from a single tumor and suggests that antiangiogenic therapies may provide an avenue for future treatment of pancreatic cancer.




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
B. Richard, R. Swanson, S. Schedin-Weiss, B. Ramirez, G. Izaguirre, P. G. W. Gettins, and S. T. Olson
Characterization of the Conformational Alterations, Reduced Anticoagulant Activity, and Enhanced Antiangiogenic Activity of Prelatent Antithrombin
J. Biol. Chem., May 23, 2008; 283(21): 14417 - 14429.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
W. Zhang, R. Swanson, Y. Xiong, B. Richard, and S. T. Olson
Antiangiogenic Antithrombin Blocks the Heparan Sulfate-dependent Binding of Proangiogenic Growth Factors to Their Endothelial Cell Receptors: EVIDENCE FOR DIFFERENTIAL BINDING OF ANTIANGIOGENIC AND ANTICOAGULANT FORMS OF ANTITHROMBIN TO PROANGIOGENIC HEPARAN SULFATE DOMAINS
J. Biol. Chem., December 8, 2006; 281(49): 37302 - 37310.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Enomoto, T. Oda, Y. Aoyagi, S. Sugiura, M. Nakajima, M. Satake, M. Noguchi, and N. Ohkohchi
Consistent Liver Metastases in a Rat Model by Portal Injection of Microencapsulated Cancer Cells
Cancer Res., December 1, 2006; 66(23): 11131 - 11139.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. Zhang, Y.-J. Chuang, T. Jin, R. Swanson, Y. Xiong, L. Leung, and S. T. Olson
Antiangiogenic antithrombin induces global changes in the gene expression profile of endothelial cells.
Cancer Res., May 15, 2006; 66(10): 5047 - 5055.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Celik, O. Surucu, C. Dietz, J. V. Heymach, J. Force, I. Hoschele, C. M. Becker, J. Folkman, and O. Kisker
Therapeutic Efficacy of Endostatin Exhibits a Biphasic Dose-Response Curve
Cancer Res., December 1, 2005; 65(23): 11044 - 11050.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
X. Zhang, E. Galardi, M. Duquette, J. Lawler, and S. Parangi
Antiangiogenic Treatment with Three Thrombospondin-1 Type 1 Repeats versus Gemcitabine in an Orthotopic Human Pancreatic Cancer Model
Clin. Cancer Res., August 1, 2005; 11(15): 5622 - 5630.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
X. Zhang, E. Galardi, M. Duquette, M. Delic, J. Lawler, and S. Parangi
Antiangiogenic Treatment with the Three Thrombospondin-1 Type 1 Repeats Recombinant Protein in an Orthotopic Human Pancreatic Cancer Model
Clin. Cancer Res., March 15, 2005; 11(6): 2337 - 2344.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
W. Zhang, Y.-J. Chuang, R. Swanson, J. Li, K. Seo, L. Leung, L. F. Lau, and S. T. Olson
Antiangiogenic antithrombin down-regulates the expression of the proangiogenic heparan sulfate proteoglycan, perlecan, in endothelial cells
Blood, February 15, 2004; 103(4): 1185 - 1191.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Giussani, G. Carrabba, M. Pluderi, V. Lucini, M. Pannacci, D. Caronzolo, F. Costa, M. Minotti, G. Tomei, R. Villani, et al.
Local Intracerebral Delivery of Endogenous Inhibitors by Osmotic Minipumps Effectively Suppresses Glioma Growth in Vivo
Cancer Res., May 15, 2003; 63(10): 2499 - 2505.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Wajih and D. C. Sane
Angiostatin selectively inhibits signaling by hepatocyte growth factor in endothelial and smooth muscle cells
Blood, March 1, 2003; 101(5): 1857 - 1863.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
Y. Cao, A. Lundwall, V. Gadaleanu, H. Lilja, and A. Bjartell
Anti-Thrombin Is Expressed in the Benign Prostatic Epithelium and in Prostate Cancer and Is Capable of Forming Complexes with Prostate-Specific Antigen and Human Glandular Kallikrein 2
Am. J. Pathol., December 1, 2002; 161(6): 2053 - 2063.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Yang, E. Baranov, J.-W. Wang, P. Jiang, X. Wang, F.-X. Sun, M. Bouvet, A. R. Moossa, S. Penman, and R. M. Hoffman
Direct external imaging of nascent cancer, tumor progression, angiogenesis, and metastasis on internal organs in the fluorescent orthotopic model
PNAS, March 19, 2002; 99(6): 3824 - 3829.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.